This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Mechanisms of action of sumatriptan and ergotamine

Authoring team

Sumatriptan:

  • highly selective agonist of the D subtype of 5-HT1 - these are located on peripheral trigeminal-nerve terminals that supply pain-sensitive vascular and meningeal structures.
  • selective for a subtype of 5-HT1 receptors located on intracranial vessels, where it mediates contraction, particularly of large arteries - the direct vasoconstrictive action of sumatriptan may also alleviate headache.
  • calcitonin-gene-related peptide is released into jugular venous blood during a migraine attack - this release is blocked by sumatriptan.
  • blocks the neuropeptide-mediated inflammatory response after trigeminal stimulation.

Ergotamine:

  • has high affinity but less selectively for 5-HT1 receptors.
  • dihydroergotamine is a potent venoconstrictor - also has arterial vasoconstrictor effects, which may alleviate headache.

Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.